- Pluri Inc. launches two new business verticals: PluriAgtech and PluriCDMO.
- PluriAgtech introduces a cell-based coffee product, offering a sustainable alternative in the coffee industry, while PluriCDMO division targets the cell and gene therapy contract development and manufacturing services.
Pluri Inc., a biotechnology firm based in Haifa, Israel, recently announced the launch of two new business verticals. These are PluriAgtech and PluriCDMO, aimed at leveraging its cell-based technology in agriculture and providing contract development and manufacturing services, respectively.
The company’s CEO, Yaky Yanay, detailed these initiatives as part of a broader strategy to drive revenue and address global challenges through innovation. “Our new business verticals are a testament to Pluri’s commitment to leveraging our cell-based technology to create sustainable and innovative solutions,” Yanay said.
PluriAgtech introduced a cell-based coffee product in January 2024, positioning itself as a sustainable alternative in the $130 billion coffee industry. The company claims this method uses 98% less water than traditional coffee production and could significantly reduce the required growing area, potentially preventing deforestation.
The newly established PluriCDMO division, also launched in January, targets the $5.2 billion cell and gene therapy sector. It offers biotech companies services from its Good Manufacturing Practice (GMP) facility, utilising proprietary 3D cell-expansion technology. This division has already started generating revenue, with several agreements under negotiation.
In addition to these new verticals, Pluri Inc. has secured a $4.2 million contract with the U.S. National Institutes of Health (NIH) to advance the development of its PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), a condition associated with nuclear radiation exposure. The company’s collaboration with Bar-Ilan University focuses on developing PLX cells to treat cocaine addiction, with Pluri entitled to a revenue share from future sales.
Stay ahead of trends and best practices
